WASHINGTON, D.C. — An international panel of scientific experts will convene on Tuesday to evaluate the U.S. measles status, but genetic data already shows the virus is once again entrenched in the United States, revoking the country’s 2019 elimination certification.

Phylogenetic analysis of 1,237 measles genomes collected from 2021 to 2023 reveals four distinct endemic lineages circulating in six states. The CDC reports 1,312 confirmed cases in the past year, a 60‑percent rise over the previous 12‑month period and the highest rate since 2012.

Public‑health labs now employ AI‑driven sequencing workflows that can deliver full viral genomes in under 24 hours. Several enterprise vendors—Illumina, Oxford Nanopore, and Thermo Fisher—are competing to provide faster, more affordable platforms, while cloud‑based analytics firms are integrating real‑time data sharing to accelerate outbreak response.

“The resurgence underscores the need for continuous surveillance and rapid data sharing,” said Dr. Maria Lopez, CDC’s chief virologist. “AI tools that flag emerging lineages in minutes rather than weeks can help us target vaccination campaigns before clusters grow.”

State health departments are investing in genomic infrastructure, allocating an estimated $12 million for 2025 to upgrade sequencing capacity. The upcoming panel will review policy options, including re‑introducing a national measles vaccination mandate and expanding genomic monitoring to private laboratories.

Key Takeaways

• Measles elimination status revoked after identification of endemic lineages.
• AI‑driven genomic surveillance enables near real‑time outbreak detection.
• Competitive landscape of sequencing vendors intensifies, driving cost reductions.

As the United States grapples with a public‑health crisis that intersects with emerging technology, the convergence of AI and genomics may prove pivotal in restoring measles elimination. The upcoming international panel will set the tone for future policy and technological collaboration.